We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
51
Ionis Pharmaceuticals
IONS
$8.81B
$11.2M 0.49%
186,244
+58,646
+46% +$3.82M
SBRA icon
52
Sabra Healthcare REIT
SBRA
$5.38B
$10.7M 0.47%
466,247
– –
ZBH icon
53
Zimmer Biomet
ZBH
$18.4B
$10.6M 0.46%
79,898
-2,146
-3% -$277K
SRPT icon
54
Sarepta Therapeutics
SRPT
$1.64B
$10.6M 0.46%
140,279
-7,568
-5% -$894K
VTR icon
55
Ventas
VTR
$44.7B
$10.3M 0.45%
141,119
+42,623
+43% +$3.03M
GSK icon
56
GSK
GSK
$104B
$9.89M 0.43%
185,406
+10,446
+6% +$537K
JAZZ icon
57
Jazz Pharmaceuticals
JAZZ
$16.2B
$9.6M 0.42%
74,936
+7,465
+11% +$1M
KYNB
58
Kyntra Bio
KYNB
$27.5M
$8.62M 0.38%
9,326
-447
-5% -$491K
ESPR
59
DELISTED
Esperion Therapeutics
ESPR
$7.83M 0.34%
213,562
+28,955
+16% +$1.15M
NVCR icon
60
NovoCure
NVCR
$1.77B
$7.55M 0.33%
100,932
+46,858
+87% +$3.75M
LTC
61
LTC Properties
LTC
$2.06B
$7.45M 0.32%
145,421
– –
ASND icon
62
Ascendis Pharma A/S
ASND
$16.5B
$7.43M 0.32%
77,167
+3,520
+5% +$393K
GWPH
63
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.42M 0.32%
64,499
– –
BPMC
64
DELISTED
Blueprint Medicines
BPMC
$7.41M 0.32%
100,916
+5,940
+6% +$513K
XRAY icon
65
Dentsply Sirona
XRAY
$2.75B
$7.3M 0.32%
136,936
+10,015
+8% +$538K
XBI icon
66
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$6.79M 0.3%
89,022
– –
MDCO
67
DELISTED
Medicines Co
MDCO
$6.78M 0.3%
135,675
-142,417
-51% -$5.68M
IMMU
68
DELISTED
Immunomedics Inc
IMMU
$6.46M 0.28%
487,103
+97,790
+25% +$1.44M
MRTX
69
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.21M 0.27%
79,687
+66,097
+486% +$6.2M
TECH icon
70
Bio-Techne
TECH
$11.2B
$5.97M 0.26%
122,148
+35,344
+41% +$1.77M
EXEL icon
71
Exelixis
EXEL
$14.1B
$5.87M 0.26%
331,751
-346,716
-51% -$7.02M
SNN icon
72
Smith & Nephew
SNN
$13.6B
$5.86M 0.26%
121,645
-39,089
-24% -$1.8M
HZNP
73
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.85M 0.26%
214,730
+57,257
+36% +$1.48M
STRO icon
74
Sutro Biopharma
STRO
$411M
$5.83M 0.25%
64,127
– –
ABMD
75
DELISTED
Abiomed Inc
ABMD
$5.82M 0.25%
32,716
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.